Cedazuridine/decitabine - Astex Pharmaceuticals
Alternative Names: ASTX-727; ASTX-727-LD; ASTX727-10; Cedazuridine/Decitabine; Decitabine/cedazuridine; Decitabine/E7727; E-7727/decitabine; Inaqovi; INQOVI; Oral C-DECLatest Information Update: 28 Aug 2024
At a glance
- Originator Astex Pharmaceuticals; National Cancer Institute (USA)
- Developer Astex Pharmaceuticals; Otsuka Pharmaceutical; Taiho Oncology; Taiho Pharma Canada
- Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Fluorinated hydrocarbons; Pyrimidine nucleosides; Ribonucleosides; Small molecules; Triazines
- Mechanism of Action Antimetabolites; Cytidine deaminase inhibitors; DNA methylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Registered Acute myeloid leukaemia
- Phase I/II Myeloproliferative disorders
- No development reported Breast cancer; Glioma; Solid tumours
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Glioma(Recurrent) in USA (PO)
- 14 Mar 2024 Pfizer completes a phase-I clinical trial in Breast cancer (Metastatic disease, Recurrent, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT04134884)